Navigation Links
Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
Date:12/24/2012

An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is increasing in prevalence.

The findings are published in the Dec. 24 online early edition of the Proceedings of the National Academy of Sciences (PNAS).

Despite the emergence of new therapies, such as tyrosine kinase inhibitors, CML and other leukemias remain problematic because some cancer stem cells avoid destruction and eventually regenerate themselves, a stem cell process known as self-renewal that can result in a return and spread (metastasis) of the disease.

In the PNAS paper, principal investigator Catriona H. M. Jamieson, MD, PhD, associate professor of medicine at UC San Diego, with colleagues in the United States, Canada and Italy, report that inflammation long associated with the development of cancer boosts activity of an enzyme called adenosine deaminase or ADAR1.

Expressed during embryogenesis to help blood cell development, ADAR1 subsequently turns off and is triggered by viral infections where it protects normal hematopoietic stem cells from attack. In leukemia stem cells, however, overexpression of ADAR1 enhances the missplicing of RNA, which leads to greater self-renewal and therapeutic resistance of malignant stem cells.

The findings build upon previous studies by Jamieson and others that elucidate the effects of RNA missplicing and instability. "People normally think about DNA instability in cancer, but in this case, it's how the RNA is edited by enzymes that really matters in terms of cancer stem cell generation and resistance to conventional therapy."

The described RNA editing process, which occurs in the context of human and other primate specific sequences, also underscores the importance of addressing inflammation as "an essential driver of cancer relapse and therapeutic resistance," Jamieson said. It also presents a new target for future therapies.

"ADAR1 is an enzyme that we may be able to specifically target with a small molecule inhibitor, an approach we have already used effectively with other inhibitors," said Jamieson. "If we can block the capacity of leukemia stem cells to use ADAR1, if we can knock down that pathway, maybe we can put stem cells back on the right track and stop malignant cloning."

CML is a cancer initiated by a mutant gene called BCR-ABL in blood forming stem cells that leads to an expansion of white blood cells and their precursors. It is typically slow-growing and often not diagnosed until its later stages when there can be a sudden, dramatic increase in malignant cells, known as blast crisis. Median age of diagnosis is 66 years; incidence of the disease increases with age. Despite tremendous advances in BCR-ABL tyrosine kinase inhibitor therapies, the majority of patients relapse if therapy is discontinued, in part as a result of dormant cancer stem cell resistance. This work suggests a novel mechanism for overcoming cancer stem cell resistance to therapy that may prevent relapse and progression.

The estimated prevalence of CML in the United States is 70,000 persons with the disease, projected to steadily increase to approximately 181,000 by 2050. CML is initiated by the mutant BCR-ABL gene, but scientists have not yet identified the cause of the mutation.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. Fast-acting enzymes with 2 fingers: Protein structurally and dynamically explained
2. Mayo Clinic researchers identify enzyme linked to prostate cancer
3. Enzymes may point toward better therapies for prediabetes
4. Synchrotron gives insight into green energy enzymes
5. Enzyme explains angina in diabetics
6. Gateway enzyme for chemicals from catnip to cancer drug
7. Structure of enzyme unravelled providing basis for more accurate design of chemotherapeutic drugs
8. Mayo Clinic researchers identify new enzyme to fight Alzheimers disease
9. Compounds activate key cancer enzyme to interfere with tumor formation
10. Enzymes implicated in disease processes attack one another instead of harming body proteins
11. Clemson researchers collect and reuse enzymes while maintaining bioactivity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Enzyme accelerates malignant stem cell cloning in chronic myeloid leukemia
(Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Leaders Engaged ... and fatal diseases in opposition to the President’s Fiscal Year 2018 Federal ... services, and hope for the most vulnerable among us. , The proposed budget ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 ... coding audit process for all medical chart types with a comprehensive set of ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... selected HealthiPASS, an innovative patient - centric payment system, to expand its focus ... improvements in the patient financial experience. , “At Ogden Clinic, we are ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... company focused on the development of a once-daily, ... or NASH, and other liver diseases, today reported ... ended December 31, 2016, and announced new and exciting ... potential direct effect on liver fibrosis. The data ...
(Date:3/23/2017)... AbbVie, a global biopharmaceutical company, today announced ... Hough is helping to raise awareness about endometriosis ... ME in EndoMEtriosis . "   The campaign, sponsored ... about and understand endometriosis, a disease affecting an estimated ... their symptoms with a healthcare professional.  Despite being one ...
(Date:3/23/2017)... Calif. , March 23, 2017   Casetabs ... of a native mobile app for the iPhone. With ... for surgery coordination and communication for physician offices, ambulatory ... native mobile app offers iPhone users even faster, more ... is making it even easier to connect care teams ...
Breaking Medicine Technology: